

Cardiovascular Standing Committee Off-Cycle Review: Measure Evaluation Meeting

**February 2, 2017
1:00 PM– 2:00 PM ET**

Please use the following information to access the conference call line and webinar:

Speaker dial-in number: 888-799-5160

Public dial-in number: 888-568-7852

Web Link: <http://nqf.commpartners.com/se/Rd/MeetingColeader.aspx?meeting.id=394206>

Registration Link: <http://nqf.commpartners.com/se/Rd/Rg.aspx?394206>

AGENDA

- | | |
|---------|--|
| 1:00pm | Welcome
<i>Mary George, MD, MSPH, FACS, FAHA, Co-Chair</i>
<i>Thomas Kottke, MD, MSPH, Co-Chair</i>
<i>Melissa Mariñelarena, RN, MPA, Senior Director</i> |
| 1:05pm | Introductions and Disclosure of Interest
<i>Marcia Wilson, PhD, MBA, Senior Vice President, Quality Measurement</i> |
| 1:10pm | eMeasure Approval for Trial Use Evaluation and Endorsement Process
<i>Melissa Mariñelarena</i> |
| 1:15pm | Review of Prior Measure Evaluation & Consideration of Candidate Measure <ul style="list-style-type: none">• 2764: Fixed dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy (NMQF)<ul style="list-style-type: none">○ Previously approved for trial use during Cardiovascular 2015-2016 project. Voting will only occur on:<ul style="list-style-type: none">▪ Reliability▪ Validity▪ Overall Suitability for Endorsement |
| 1:45pm | NQF Member and Public Comment |
| 2:00 pm | Adjourn |